These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 38929568

  • 1. Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer.
    Kınıkoğlu O, Odabas H, Altıntaş YE, Yıldız A, Çakan B, Akdağ G, Yıldırım S, Bal H, Kaya T, Tünbekici S, Işık D, Başoğlu T, Yıldırım ME, Turan N.
    Medicina (Kaunas); 2024 Jun 07; 60(6):. PubMed ID: 38929568
    [Abstract] [Full Text] [Related]

  • 2. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
    Al Rabadi LS, Cook MM, Kaempf AJ, Saraceni MM, Savin MA, Mitri ZI.
    BMC Cancer; 2021 Oct 27; 21(1):1150. PubMed ID: 34706686
    [Abstract] [Full Text] [Related]

  • 3. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
    Yokoe T, Kurozumi S, Nozawa K, Ozaki Y, Maeda T, Yazaki S, Onishi M, Fujimoto A, Nakayama S, Tsuboguchi Y, Iwasa T, Sakai H, Ogata M, Terada M, Nishimura M, Onoe T, Masuda J, Kurikawa M, Isaka H, Hagio K, Shimomura A, Okumura Y, Futamura M, Shimokawa M, Takano T.
    Breast Cancer; 2021 May 27; 28(3):581-591. PubMed ID: 33389616
    [Abstract] [Full Text] [Related]

  • 4. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.
    Conte B, Fabi A, Poggio F, Blondeaux E, Dellepiane C, D'Alonzo A, Buono G, Arpino G, Magri V, Naso G, Presti D, Mura S, Fontana A, Cognetti F, Molinelli C, Pastorino S, Bighin C, Miglietta L, Boccardo F, Lambertini M, Del Mastro L, Gruppo Italiano Mammella (GIM) study group.
    Clin Breast Cancer; 2020 Apr 27; 20(2):e181-e187. PubMed ID: 31735691
    [Abstract] [Full Text] [Related]

  • 5. Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment.
    Watanuki R, Shimomura A, Yazaki S, Noda-Narita S, Sumiyoshi-Okuma H, Nishikawa T, Tanioka M, Sudo K, Shimoi T, Noguchi E, Yonemori K, Tamura K.
    Medicine (Baltimore); 2020 Sep 18; 99(38):e22331. PubMed ID: 32957402
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population.
    Noda-Narita S, Shimomura A, Kawachi A, Sumiyoshi-Okuma H, Sudo K, Shimoi T, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.
    Breast Cancer; 2019 Jul 18; 26(4):492-498. PubMed ID: 30737616
    [Abstract] [Full Text] [Related]

  • 7. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA, Stanzel S, Patre M, Ellis PA.
    BMC Cancer; 2019 May 30; 19(1):517. PubMed ID: 31146717
    [Abstract] [Full Text] [Related]

  • 8. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
    Hurvitz SA, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Egorov A, Liu Y, Cathcart J, Bako E, Tecson K, Verma S, Cortés J.
    ESMO Open; 2024 May 30; 9(5):102924. PubMed ID: 38796287
    [Abstract] [Full Text] [Related]

  • 9. Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer.
    Migeotte A, Dufour V, van Maanen A, Berliere M, Canon JL, Taylor D, Duhoux FP.
    BMC Cancer; 2021 Nov 11; 21(1):1204. PubMed ID: 34763656
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.
    DeBusk K, Abeysinghe S, Vickers A, Nangia A, Bell J, Ike C, Forero-Torres A, Blahna MT.
    Future Oncol; 2021 Nov 11; 17(33):4635-4647. PubMed ID: 34463120
    [Abstract] [Full Text] [Related]

  • 11. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
    Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P.
    J Clin Oncol; 2017 Jan 10; 35(2):141-148. PubMed ID: 28056202
    [Abstract] [Full Text] [Related]

  • 12. The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience.
    Kolarov Bjelobrk I, Radic J, Trifunovic J, Pesic J, Vidovic V, Vranjkovic B, Petrovic N, Andrejic Visnjic B.
    J Chemother; 2022 Jul 10; 34(4):264-271. PubMed ID: 34844517
    [Abstract] [Full Text] [Related]

  • 13. Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER-2 positive breast cancer: systematic review and network meta-analysis.
    Ciapponi A, Bardach A, Colaci C, Rodríguez Cairoli F, Argento F, Korbenfeld E, García Martí S.
    Rev Peru Med Exp Salud Publica; 2024 May 27; 41(1):7-18. PubMed ID: 38808848
    [Abstract] [Full Text] [Related]

  • 14. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
    Martin M, Fumoleau P, Dewar JA, Albanell J, Limentani SA, Campone M, Chang JC, Patre M, Strasak A, de Haas SL, Xu J, Garcia-Saenz JA.
    Ann Oncol; 2016 Jul 27; 27(7):1249-56. PubMed ID: 27052654
    [Abstract] [Full Text] [Related]

  • 15. Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer.
    Iwata H, Xu B, Kim SB, Chung WP, Park YH, Kim MH, Tseng LM, Chung CF, Huang CS, Kim JH, Chiu JWY, Yamashita T, Li W, Egorov A, Nishijima S, Nakatani S, Nishiyama Y, Sugihara M, Cortés J, Im SA.
    Cancer Sci; 2024 Sep 27; 115(9):3079-3088. PubMed ID: 38979893
    [Abstract] [Full Text] [Related]

  • 16. Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Huober J, Weder P, Ribi K, Thürlimann B, Thery JC, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye AM, Müller A, Membrez-Antonioli V, Gérard MA, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H, Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group.
    JAMA Oncol; 2023 Oct 01; 9(10):1381-1389. PubMed ID: 37561451
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.
    Moinard-Butot F, Saint-Martin C, Pflumio C, Carton M, Jacot W, Cottu PH, Diéras V, Dalenc F, Goncalves A, Debled M, Patsouris A, Mouret-Reynier MA, Vanlemmens L, Leheurteur M, Emile G, Ferrero JM, Desmoulins I, Uwer L, Eymard JC, Cheaib B, Courtinard C, Bachelot T, Chevrot M, Petit T.
    Breast; 2022 Jun 01; 63():54-60. PubMed ID: 35299035
    [Abstract] [Full Text] [Related]

  • 18. Lower response to trastuzumab emtansine in metastatic breast cancer patients with human epidermal growth factor receptor 2 immunohistochemistry score of 2 and fluorescence in situ hybridization positive compared with immunohistochemistry score of 3: a retrospective study.
    Yazaki S, Hashimoto J, Ogita S, Nakano E, Suzuki K, Yamauchi T.
    Anticancer Drugs; 2020 Oct 01; 31(9):973-978. PubMed ID: 32868644
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial.
    Cortés J, Diéras V, Lorenzen S, Montemurro F, Riera-Knorrenschild J, Thuss-Patience P, Allegrini G, De Laurentiis M, Lohrisch C, Oravcová E, Perez-Garcia JM, Ricci F, Sakaeva D, Serpanchy R, Šufliarský J, Vidal M, Irahara N, Wohlfarth C, Aout M, Gelmon K.
    JAMA Oncol; 2020 Aug 01; 6(8):1203-1209. PubMed ID: 32584367
    [Abstract] [Full Text] [Related]

  • 20. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.
    Montemurro F, Ellis P, Anton A, Wuerstlein R, Delaloge S, Bonneterre J, Quenel-Tueux N, Linn SC, Irahara N, Donica M, Lindegger N, Barrios CH.
    Eur J Cancer; 2019 Mar 01; 109():92-102. PubMed ID: 30708264
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.